Evidence map›Paper›PMID 28529741›Full record

ArticleMolecular and clinical oncology2017

Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report.

Iosune Baraibar, Almudena Quílez, Diego Salas, Marta Román, Christian Rolfo, José L Pérez-Gracia, Ignacio Gil-Bazo

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Pazopanib-Induced Asymptomatic Necrotizing Pancreatitis Diagnosed onIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Iosune BaraibarDepartment of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Almudena QuílezDepartment of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
Diego SalasDepartment of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Marta RománDepartment of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Christian RolfoPhase I - Early Clinical Trials Unit, Antwerp University Hospital, Edegem, Belgium.
José L Pérez-GraciaDepartment of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Ignacio Gil-BazoDepartment of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Clinica Universidad de Navarra · ESAntwerp University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The universal clinical use of multi-targeted tyrosine kinase inhibitors (TKIs) in patients diagnosed with advanced renal cell carcinoma (RCC) has significantly prolonged their estimated survival times and their quality of life. However, several adverse side-effects associated predominantly with the inhibition of the vascular endothelial growth factor receptor by these drugs may prove to be potentially life-threatening. One adverse event that is only rarely observed with the use of TKIs in this clinical setting is acute pancreatitis. In the present study, to the best of our knowledge, the first case of asymptomatic radiological acute pancreatitis associated with the use of pazopanib in monotherapy in a patient with RCC is presented. In addition, a comprehensive review of the literature on this topic is provided, and certain potential measures that may aid in early diagnosis and treatment are discussed.

Indexed as

acute pancreatitispazopanibrenal cell carcinomatoxicitytyrosine kinase inhibitors

Identifiers

PMID28529741
PMCPMC5431634
OpenAlexW2604689231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.